Should I tell my doctor I'm using peptides?
Yes. Even if your doctor isn't familiar with research peptides, disclosure improves bloodwork interpretation, drug-interaction checks, and acute-care safety.
Updated May 8, 2026 · 5 min read
Yes — disclose. Most general-practice doctors aren't familiar with research peptides, but disclosure still matters for bloodwork interpretation, drug-interaction screening, and acute-care safety. The downside of disclosing is a possibly awkward conversation; the downside of not disclosing is a clinician misreading lab drift, prescribing something that interacts, or making decisions in an emergency without full information. Have the conversation, bring evidence, expect a range of reactions, and don't expect protocol guidance.
Why disclosure matters
| Reason | What it changes |
|---|---|
| Lab interpretation | An elevated IGF-1 means something different if your doctor knows you're running Sermorelin |
| Drug interactions | Especially relevant if you start a new prescription |
| Pre-existing condition flags | Cancer history, diabetes, cardiovascular issues all change peptide risk |
| Emergency context | If you end up in the ER, the chart should reflect what's in your body |
| Continuity of care | Future symptoms can be misattributed without the full picture |
A clinician working with incomplete information is more likely to make a wrong call than one working with complete information, even if they're skeptical of what you're doing.
What to expect from the doctor's reaction
Reactions split roughly into three categories:
| Reaction | Frequency | What to do |
|---|---|---|
| Curious / supportive | Less common | Ask if they'll order monitoring labs; treat as an asset |
| Unfamiliar but neutral | Most common | Provide your protocol and research; ask for monitoring |
| Hostile / dismissive | Common enough | Hear them out, decide whether to continue or find another clinician |
A hostile reaction isn't necessarily wrong — peptides have real risks and limited human data. It is information, though. If you fundamentally disagree with the recommendation, you have a choice between modifying behavior or finding a more aligned clinician (see do I need a doctor for peptides?).
How to have the conversation
The framing that tends to go best:
"I've started using a research peptide called [name]. I want you to know what's in my system and I'd like baseline bloodwork so we have a reference point. I'm not asking for a prescription — these aren't prescription compounds — just for monitoring."
That framing accomplishes three things: it discloses, it sets a clear ask (monitoring labs), and it removes the implicit expectation that the clinician will validate or prescribe. It tends to defuse the most common reflex (which is "I can't prescribe that").
What to bring:
- The peptide name, your dose, your cadence, when you started
- A one-page summary of what the peptide is and what's known about it
- Your specific monitoring ask (CBC, CMP, lipids, fasting glucose, HbA1c, IGF-1 if running secretagogues)
- Your goal in plain language
What not to bring:
- A printed protocol from a Reddit thread as your evidence
- An expectation that they'll endorse or prescribe
- Defensiveness — they're allowed to disagree
What to disclose specifically
| Detail | Why |
|---|---|
| Compound name | Name and class (e.g., "Sermorelin, a GH secretagogue") |
| Dose and cadence | Affects what's plausible in lab work |
| Start date | Frames the timeline of any new symptoms |
| Vendor / source | Useful if a contamination question arises |
| Goal | Helps the clinician weigh risk vs benefit honestly |
| Other supplements / drugs | Standard interaction check |
Keep it factual and concise. The clinician doesn't need a research review — they need the data points.
Doctors more likely to engage constructively
If your PCP is reflexively hostile and you want a more engaged second opinion, these specialties tend to be more familiar with peptides:
- Functional medicine / integrative medicine
- Anti-aging / longevity clinics
- Men's health / TRT-focused clinics
- Sports medicine (especially with athlete patients)
- Endocrinology (varies — some are open, some are firmly skeptical)
A clinician who's never heard of BPC-157 is the median, not an outlier. That alone isn't a reason to hide it from them.
When disclosure is non-negotiable
Some scenarios where not disclosing is a real problem:
- Pre-surgery / anesthesia consult — anything affecting tissue healing or coagulation is relevant
- Pregnancy or planning pregnancy — most peptides should not be used; the clinician needs to know
- Cancer screening or workup — IGF-1 axis modulation is directly relevant
- Cardiac workup — water retention, BP changes, heart-rate effects matter
- Emergency room visit for any reason — the chart should reflect what's in your body
- Starting a new prescription — interaction checks need full information
In any of these contexts, the cost of withholding information rises sharply.
What disclosure does not obligate you to do
Telling your doctor doesn't mean you have to stop. It doesn't mean you have to follow their protocol advice (most won't have any). It doesn't mean you've "given them the right" to write anything in your chart that ends future insurance options — clinicians chart what they observe regardless. Disclosure is a one-way information transfer; what you do with their reaction is still your call.
A note on records
Some users worry that disclosed peptide use will affect insurance, life-insurance underwriting, or future care. In practice, an off-label supplement note in a chart is rarely a meaningful flag. Untreated drift in HbA1c or IGF-1 because no one knew to look — that's the bigger long-term risk to records and outcomes.